Benchmark reissued their buy rating on shares of Surgery Partners (NASDAQ:SGRY – Free Report) in a research report released on Wednesday, Benzinga reports. Benchmark currently has a $50.00 price target on the stock.
A number of other equities analysts also recently issued reports on SGRY. Macquarie began coverage on Surgery Partners in a research note on Friday, June 28th. They set an outperform rating and a $31.00 price target for the company. Citigroup cut their target price on Surgery Partners from $38.00 to $36.00 and set a buy rating on the stock in a research note on Wednesday. Cantor Fitzgerald restated an overweight rating and issued a $43.00 target price on shares of Surgery Partners in a research note on Tuesday, July 9th. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $49.00 price objective on shares of Surgery Partners in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and an average price target of $39.86.
Read Our Latest Report on Surgery Partners
Surgery Partners Trading Down 0.8 %
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. Surgery Partners had a positive return on equity of 3.00% and a negative net margin of 1.17%. The firm had revenue of $762.10 million during the quarter, compared to analyst estimates of $735.94 million. During the same period last year, the company posted $0.25 EPS. The business’s quarterly revenue was up 14.2% on a year-over-year basis. Sell-side analysts expect that Surgery Partners will post 0.88 EPS for the current fiscal year.
Insider Activity
In other news, insider Bradley R. Owens sold 6,000 shares of Surgery Partners stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $27.65, for a total transaction of $165,900.00. Following the completion of the transaction, the insider now directly owns 72,338 shares in the company, valued at $2,000,145.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.30% of the company’s stock.
Hedge Funds Weigh In On Surgery Partners
A number of hedge funds have recently added to or reduced their stakes in SGRY. Janus Henderson Group PLC raised its holdings in Surgery Partners by 7,987.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,504,248 shares of the company’s stock worth $74,701,000 after acquiring an additional 2,473,282 shares during the last quarter. Iron Triangle Partners LP bought a new stake in Surgery Partners in the 4th quarter worth approximately $33,415,000. Norges Bank bought a new stake in Surgery Partners in the 4th quarter worth approximately $25,765,000. Vanguard Group Inc. grew its position in Surgery Partners by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 7,417,609 shares of the company’s stock worth $237,289,000 after purchasing an additional 698,845 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in Surgery Partners by 26.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,801,091 shares of the company’s stock worth $66,643,000 after purchasing an additional 589,499 shares during the period.
Surgery Partners Company Profile
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Featured Articles
- Five stocks we like better than Surgery Partners
- Stock Dividend Cuts Happen Are You Ready?
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- What Are Growth Stocks and Investing in Them
- MarketBeat Week in Review – 8/5 – 8/9
- Best Aerospace Stocks Investing
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.